Nanotechnologies

Such a platform may provide new therapeutic opportunities for the treatment of back -of-the-eye diseases such as Age-Related Macular Degeneration (AMD).

Pic.1

We are engaged in the development of an innovative formulation that, if successful, would allow the delivery of drugs to the retina through eye drops (Pic. 1).

This way we would be able to respond to patients’ demand for comfort, efficacy and safety thus avoiding intra-vitreal injections.